Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Senior Staff Has Final Say Over Disputes In Enzi/Kennedy Bill

This article was originally published in The Tan Sheet

Executive Summary

Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
Advertisement

Related Content

FDA Safety Plan Is Only First Step, But Agency Says No New Authority Needed
FDA Safety Plan Is Only First Step, But Agency Says No New Authority Needed
FDA Safety Plan Is Only First Step, But Agency Says No New Authority Needed
Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation
Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
GAO Drug Safety Report Recommends Giving Teeth To FDA Postmarket Review
GAO Drug Safety Report Recommends Giving Teeth To FDA Postmarket Review
PhRMA Guidelines May Redraw Line Between DTC, OTC Advertising
FDA Safety Center Authority Would Extend To OTCs Under Grassley Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS099674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel